Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV LID ΔM2-2 1030s Vaccine in RSV-Seronegative Infants
NCT02794870Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2016
- Primary completion
- Jul 2017
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing RSV LID ΔM2-2 1030s with Placebo (2 arms). Primary endpoints: Number of Participants With Solicited Adverse Events (AEs) by Grade, Number of Participants With Unsolicited AEs by Grade and 6 more. Started Jul 2016; status: completed.
02
Drugs
RSV LID cp ΔM2-2
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02794870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02794870.